Celsius, Lucid, and Signet Rank in Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21)
outlook.
Arcutis Biotherapeutics, Inc. ARQT stock gained 16.35% last week after Health Canada approved its Zoryve cream for treating mild to moderate atopic dermatitis.
Lucid Group Inc. LCID stock increased 15.79% after Morgan Stanley upgraded the stock from Underweight to Equal-Weight.
Catalyst Pharmaceuticals CPRX stock upped 15.27%, while StoneCo STNE shares were up 14.20% following favorable fourth-quarter EPS and sales reports.
In the past week, Diginex Limited experienced a significant spike of 108.29%, reflecting market improvement following uncertainties among investors and various risk factors that saw the market entering correction territory.
NextDecade Corporation also saw positive movement with shares rising by 25.07%. The company’s announcement of the U.S. Court of Appeals revising a past judgment contributed to this uptick by removing vacatur risk on the Federal Energy Regulatory Commission’s order.
Celsius Holdings Inc. registered a 21.60% increase in stock value, possibly in response to the news of PepsiCo Inc.’s acquisition of the prebiotic soda brand, Poppi, for a hefty sum of $1.95 billion.
Meanwhile, Signet Jewelers Ltd experienced a 21.08% surge in stock prices following the disclosure of fourth-quarter FY25 earnings, prompting several analysts to reassess the stock’s price forecast.
New Fortress Energy Inc. witnessed a 20.63% rise in shares as the dollar weakened due to U.S. strikes on Houthi targets, along with optimistic Chinese economic data projecting increased demand.
Millrose Properties, Inc. shares grew by 16.61% after the company announced its first dividend payout and laid out its projections for 2025.
Additionally, Arcutis Biotherapeutics, Inc. saw a 16.35% stock increase after gaining approval from Health Canada for its Zoryve cream designed to treat mild to moderate atopic dermatitis.
In line with positive stock performance, Lucid Group Inc.’s stock saw a 15.79% rise subsequent to an upgrade by Morgan Stanley from Underweight to Equal-Weight.
Catalyst Pharmaceuticals experienced a 15.27% increase in stock value, while StoneCo observed a 14.20% rise after reporting better-than-expected fourth-quarter EPS and sales figures.
Overall, these ten mid-cap stocks emerge as the top performers of the past week, showcasing noteworthy gains that may prompt investors to consider them for inclusion in their portfolios.
